Haerbin
Haerbin
Haerbin, China11 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) | eye disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07867080 | |
| A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | Acute Ischemic Stroke, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-29 | NCT07361302 | |
| Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Not applicable | 2026-09-28 | NCT07180212 | |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT06868277 | |
| A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients | Pan-tumor(NSCLC, GYN Cancers, BTC and UC) | Recruiting | Not stated | 2026-09-24 | NCT07404202 | |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-08-06 | NCT06203210 | |
| Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture | Bone Diseases, Metabolic, Nutritional and Metabolic Diseases, Osteoporotic Fractures, bone disorder, bone fracture, injury, metabolic disease, musculoskeletal system disorder, osteoporosis | Recruiting | Not applicable | 2026-01-12 | NCT05866029 | |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 | 2025-10-20 | NCT05627063 | |
| Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Not stated | 2025-07-31 | NCT05444491 | |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, lung disorder, mycobacterial infectious disease, pulmonary tuberculosis, respiratory system disorder, respiratory tract infectious disorder, rifampicin-resistant tuberculosis, tuberculosis | Active, not recruiting | Phase 3 | 2025-04-01 | NCT06081361 | |
| A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold | Infections, Picornaviridae infectious disease, RNA Virus Infections, common cold, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Recruiting | Phase 3 | 2024-11-20 | NCT06697886 |